HAEMATO Past Earnings Performance

Past criteria checks 2/6

HAEMATO has been growing earnings at an average annual rate of 2578%, while the Healthcare industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 2.5% per year. HAEMATO's return on equity is 6.4%, and it has net margins of 3.7%.

Key information

2,578.0%

Earnings growth rate

2,605.8%

EPS growth rate

Healthcare Industry Growth12.6%
Revenue growth rate2.5%
Return on equity6.4%
Net Margin3.7%
Last Earnings Update30 Jun 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How HAEMATO makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0VZ7 Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 232611040
31 Mar 23254950
31 Dec 22248850
30 Sep 22251460
30 Jun 22254070
31 Mar 22270370
31 Dec 21285780
30 Sep 21280670
30 Jun 21274570
31 Mar 21256070
31 Dec 20238-570
30 Sep 20229-370
30 Jun 20220-270
31 Mar 20209-270
31 Dec 19198-160
30 Sep 19211-160
30 Jun 19224-160
31 Mar 19249360
31 Dec 18274660
30 Sep 18284860
30 Jun 182941060
31 Mar 18292860
31 Dec 17289760
30 Sep 17281860
30 Jun 17272950
31 Mar 172741050
31 Dec 162761150
30 Sep 16273950
30 Jun 16271760
31 Mar 16250660
31 Dec 15230650
30 Sep 15210570
30 Jun 15190550
31 Mar 15196650
31 Dec 14203750
30 Sep 142149-10
30 Jun 142241040
31 Mar 14199940
31 Dec 13174800
30 Sep 13126730

Quality Earnings: 0VZ7 has a large one-off gain of €2.9M impacting its last 12 months of financial results to 30th June, 2023.

Growing Profit Margin: 0VZ7's current net profit margins (3.7%) are higher than last year (0.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 0VZ7's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare 0VZ7's past year earnings growth to its 5-year average.

Earnings vs Industry: 0VZ7 earnings growth over the past year (2578%) exceeded the Healthcare industry -0.8%.


Return on Equity

High ROE: 0VZ7's Return on Equity (6.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/07/08 10:51
End of Day Share Price 2024/04/10 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

HAEMATO AG is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward AcklinFirst Berlin Equity Research GmbH
Cosmin FilkerGBC AG
Christian EhmannWarburg Research GmbH